DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer

Information source: SCRI Development Innovations, LLC
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Breast Cancer

Intervention: Liposomal Doxorubicin (Drug); Docetaxel (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: SCRI Development Innovations, LLC

Official(s) and/or principal investigator(s):
Denise A. Yardley, MD, Principal Investigator, Affiliation: SCRI Development Innovations, LLC

Summary

The efficacy of single agent liposomal doxorubicin as compared to single agent docetaxel will be evaluated as first line treatment in metastatic breast cancer patients, with subsequent crossover to the opposite arm at disease progression or patient intolerance. We will explore this as well as any possible cross resistance between these two agents.

Clinical Details

Official title: A Phase II Randomized Crossover Study Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment

Secondary outcome: Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease.

Detailed description: Upon determination of eligibility, patients will be randomly assigned to one of two treatment arms:

- Liposomal Doxorubicin

- Docetaxel

For ever 2 patients treated, 1 will receive treatment A (Liposomal Doxorubicin) and 1 will receive treatment B (Docetaxel). Patients demonstrating progression on either ARM will be eligible for cross over to treatment in the other ARM, provided patient still meets the eligibility laboratory and performance status criteria. The study is not blinded so both the patient and the doctor will know which treatment has been assigned.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: To be included in this study, you must meet the following criteria:

- Metastatic breast cancer confirmed by biopsy

- Prior adjuvant/neoadjuvant treatment allowed

- Measurable disease

- Able to perform activities of daily living with minimal assistance

- Age 18 years or older

- Adequate bone marrow, liver and kidney function

- Normal heart function

- Written informed consent

Exclusion Criteria: You cannot participate in this study if any of the following apply to you:

- Pre-existing moderate peripheral neuropathy

- History of significant heart disease

- Meningeal metastases.

- Prior chemotherapy for metastatic breast cancer

- No measurable disease (including bone only, pleural effusions, etc.)

- Receiving Herceptin therapy.

- Women who are pregnant or lactating.

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Locations and Contacts

Tennessee Oncology, Nashville, Tennessee 37203, United States
Additional Information

Published article in Clinical Breast Cancer

Starting date: February 2001
Last updated: July 24, 2013

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017